Drug
GS 5885
GS 5885: highest development phase Phase 2, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| GS-5885 NCT01435226 | Phase 2 | Hepatitis C, Chronic |
Latest
No recent events.
Follow GS 5885 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.